By
Comprising a large and fast-growing group of medications with diverse therapeutic targets, monoclonal antibodies (mAbs) have a wide-ranging variety of current and potential therapeutic applications. The first mAb was generated in 1975, and the first mAb muromonab-CD3, a mouse antibody used to prevent kidney transplant rejection, was approved by the United States Food and Drug Administration (FDA) in 1986.1
* References can be found in the original article via the link below.
Read Article
